Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial
四价重组COVID-19蛋白疫苗SCTV01E在3至17岁儿童和青少年中的安全性和免疫原性:一项随机、双盲、安慰剂对照的II期临床试验
期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines13010043
Zhu, Fengcai; Huang, Ting; Jin, Pengfei; Zhang, Linglin; Jin, Zhongqiang; Zhang, Wenli; Yuan, Dongya; Wang, Zhong; Deng, Yusong; Li, Jiaxin; Shen, Xiao; Fu, Yongpan; Li, Jian; Yang, Xinjie; Li, Jing; Xie, Liangzhi